{"prompt": "['Figure 2. Study Design', 'ARM A: Supervised Exercise (SE) Group', '12 cycle supervised exercise programme', '1 cycle=28 days', 'Cycle 0: x3 days/week (flex entry allowed - see pg 31)', 'Cycles 1-8: x2 days/week', 'Cycles 9-11: x1 day/week', '12 cycle self-managed exercise programme', 'Behavioural support (text messages)', 'Psychosocial support (monthly newsletters)', 'Baseline', 'Exercise assessments (Cycles 0, 6, 9, 12, 18, 24)', 'Assessments', 'Constant Load Tests (Cycles 0-24)', 'Initial Study', 'Exercise', 'Frequent exercise monitoring (Cycles 0-12)', 'Procedures', 'Metabolic biomarker assessments (Cycles 0, 6, 12, 24)', 'Recruitment', 'Blood/Urine', 'Collection', 'Qol and other patient-reported outcomes (Quarterly', 'Consent', 'from Cycle 3, then yearly)', 'Screening', 'QOL', 'Pain', 'ARM B: Self-directed Exercise (SDE) Group', 'Sleep', 'Fatigue', 'Exercise guidelines', 'Psychosocial support (monthly newsletters)', 'Exercise assessments (Cycles 0, 6, 12, 18, 24)', 'Metabolic biomarker assessments (Cycles 0, 6, 12, 24)', 'QoL and other patient-reported outcomes (Quarterly', '2.0 OBJECTIVES', 'Primary Objective:', '2.1 To determine if high intensity aerobic and resistance training plus psychosocial support increases', 'overall survival compared to psychosocial support alone in patients with metastatic castrate-', 'resistant prostate cancer.', 'Secondary Objectives:', '2.2 To compare progression free survival between the intervention and control groups.', '2.3 To compare the time to first occurrence of a symptomatic skeletal-related event between the', 'intervention and control groups.', '2.4 To compare time to progression of pain, degree of pain, and opiate use between the intervention', 'and control groups.', '2.5 To compare change in levels of inflammation, energy metabolism, and androgen metabolism', 'biomarkers between the intervention and control groups over time.', '2.6 To determine whether biomarkers of inflammation, energy metabolism, and androgen metabolism', 'are associated with overall survival and explore the extent to which these biomarkers mediate the', 'hypothesized association between exercise and overall survival.', '2.7 To compare physical and emotional quality of life between the intervention and control groups', '3.0 ELIGIBILITY CRITERIA', '3.1 Inclusion Criteria', 'INTERVAL Protocol Version 4.0, 19 April 2018', '12']['Patients must be mCRPC. This is defined as adenocarcinoma of the prostate with systemic', 'metastatic disease despite castrate levels of testosterone (<50 ng/dL) due to orchiectomy or', 'LHRH agonist.', 'Patients must have one or more of the following to be considered mCRPC', 'Metastatic Disease Progression: >20% increase in the sum of diameters of', 'measurable lesions from the time of maximal regression or appearance of', 'one or more new lesions.', 'Bone Scan Progression: Appearance of one or more new lesions on bone', 'scan attributable to prostate cancer.', 'PSA Progression: PSA >2 ng/ml that has risen serially on at least two', 'occasions, each at least one week apart (PSA1 < PSA2 < PSA3).', 'Castrate levels of testosterone must be maintained while on study. Be on androgen', 'deprivation therapy (ADT) with a GnRH agonist/antagonist or prior bilateral orchiectomy. All', 'patients will be required to be on ADT during the study period or have had a prior bilateral', 'orchiectomy. Men with small cell neuroendocrine tumours or features of small cell disease', 'are not eligible.', 'At enrolment, patients must fit into one of the following 4 categories:', '1. Treatment na\u00efve for mCRPC (have not yet started approved therapies for CRPC', 'ie: Abiraterone/Enzalutamide/Apalutamide/Docetaxel; less than 4 weeks on', 'approved therapies is still considered to be treatment na\u00efve)', 'Or', '2.', 'Receiving Abi/Enza/Apa for mCRPC AND responding or stable (PSA values must', 'be stable or declining after at least 4 weeks since starting Abi/Enza/Apa for', 'mCRPC)', 'Or', '3. Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they', 'are asymptomatic AND there is no intent on starting chemotherapy within 6', 'months', 'Or', '4. Patients treated with Docetaxel as first line therapy for mCRPC who are', 'asymptomatic without ANY evidence of progression', 'Or', '5. Patients may have progressed following Docetaxel first line and are now', 'receiving treatment with Abi/Enza/Apa. These patients must absolutely be', 'responding or stable (PSA values must be stable or declining after starting', 'Abi/Enza/Apa treatment) and have an expected life expectancy of more than', '1', 'year.', '>4 weeks since any major surgery and fully recovered.', 'Halabi Nomogram score <195\u00b9 (Risk Category rated as low or intermediate risk)', 'Age >18 years', 'Eastern Cooperative Oncology Group (ECOG) performance status 0-1', 'Patients must be able to travel to one of the study-designated exercise facilities up to three', 'days per week for four weeks during cycle 0, two days per week for cycles 1-8 (32 weeks) and', 'once per week for cycles 9-11 (12 weeks). In addition, patients must be able to attend exercise', 'testing visits as outlined in the Table 1.', 'Required Initial Laboratory Values:', 'Absolute neutrophil count (ANC) 1500/uL', 'Platelet count 100,000/uL', 'Creatinine 1.5 X upper limits of normal', 'Bilirubin 1.5 X upper limits of normal', 'Aspartate aminotransferase (AST) 1.5 X upper limits of normal', 'Serum testosterone 50 ng/dL', 'INTERVAL Protocol Version 4.0, 19 April 2018', '13']\n\n###\n\n", "completion": "END"}